Caused by parasites transmitted through the bites of infected mosquitoes, malaria puts nearly 3.2 billion people – almost half of the world’s population – at risk of disease. Malaria has flu-like symptoms, including fever, joint pain, headaches, frequent vomiting, convulsions and coma.
Every year, malaria kills more than 600,000 people and infects more than 200 million. Ninety percent of these deaths occur in sub-Saharan Africa. Malaria is a source of poverty as it often leaves its victims unable to work, become educated or take care of their families. While there are drugs available to treat the disease, there is a need for a malaria vaccine.
Development of a vaccine to protect those living in malaria-prone regions would greatly decrease sickness and death in these areas and may be the only way to make a large impact on the disease in some countries.
IDRI is a leading developer of adjuvants that stimulate the immune system. We have built a portfolio of proprietary adjuvants and are using our adjuvant technologies to empower the immune system to recognize and destroy malaria parasites. Data suggest that adjuvants will be an essential part of a successful malaria vaccine, and our adjuvants have been proven in preclinical models of malaria. We are working with collaborators to use our adjuvants as a component of a malaria vaccine.